Nagar SP, Sato M, Montgomery W, Nakamura T, Imagawa H, Davis KL. Treatment patterns and characteristics of adult patients with attention deficit/hyperactivity disorder receiving atomoxetine in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A305.
Francois C, Danchenko N, Williams V, Nelson L, Williams NJ, Yarr S, DiBenedetti DB, Lancon C. Validation of the depression and family functioning scale (DFFS). Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A24.
Novick D, Montgomery W, Aguado J, Duenas H, Haro JM. Symptomatic factors in patients with major depressive disorder (MDD): results from an observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A543.
Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Comparative effectiveness in terms of treatment discontinuation of orodispersable versus standard oral olanzapine tablets in non-adherent patients: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A766.
Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A455.
von Scheele B, Mauskopf J, Brodtkorb T, Ainsworth C, Galani Berardo C, Patel A. Relationship between modelling approach and reported outcomes: case studies of models for the treatment of schizophrenia. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A589.
Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Factors associated with pain persistence in patient with depression during a 3-month follow-up period. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Amsterdam, The Netherlands. [abstract] Value Health. 2013 Nov; 16(7):A544.
Forsyth B, Fehnel SE, Danchenko N, Franois C, Brevig T. Assessing impacts of major depressive disorder (MDD) on cognitive function. Value Health. 2012 Nov 1;15(7):A341.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012 Jan 1;15(1):55-64.
Stull DE, Houghton K. Examining variability in depression among pre-retirees: innovative analytic methods applied to observational data. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A301.
Ascher-Svanum H, Novick D, Haro J, Aguado J, Cui Z, Anand H. Empirically-driven definitions of 'good', 'moderate' and 'poor' levels of functioning in the treatment of schizophrenia. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A287. doi: 10.1016/j.jval.2011.08.307
Lançon C, DiBenedetti DB, Lewis SA, Davis KH, Danchenko N, François C. Assessing the impact of major depressive disorder (MDD) on family functioning: development of the depression and family functioning scale. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD. [abstract] Value Health. 2011 May; 14(3):A195.
Meyers J, Classi P, Wietecha LA, Candrilli S. The burden of attention-deficit/hyperactivity disorder (ADHD) on patients hospitalized with a primary diagnosis of oppositional defiant disorder (ODD). Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A182.
Classi P, Meyers J, Wietecha L, Candrilli S. Characteristics of hospitalizations for attention-deficit/hyperactivity disorder (adhd) among children and adolescents in the united states from 2000-2006. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A111.
Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.
Hong J, Reed C, Novick D, Haro JM, Aguado J. Clinical and economic consequences of medication nonadherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A355.
Khan SB, Zagar AJ, Hayes CP, DiBenedetti DB, Zhou X, Price M, Van Brunt DL. Assessment of type 2 Diabetes mellitus patients with and without symptoms of ADHD: patient characteristics and resource utilization data from an internet-based survey. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 15, 2009. Orlando, FL. [abstract] Value Health. 2009 May 1; 12(3):A181-2.
Lee S, Lang K, Jackel J, Crivera C, Dirani R, Menzin J. Predictors of medication adherence among schizophrenia patients treated with conventional and atypical antipsychotics in a large state medicaid program. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada. [abstract] Value Health. 2008 May; 11(3):A123.
Leeuwenkamp O, Morlock R, Bell C, Brogan AJ, Mauskopf J. Costs and outcomes of atypical antipsychotics for the treatment of acute schizophrenia. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A301.
Meads DM, McKenna SP, Doward LC. Assessing the cross-cultural comparability of the Centre for Epidemiologic Studies Depression scale (CES-D). Poster presented at the 2006 ISPOR 9th Annual European Congress; October 2006. Copenhagen, Denmark. [abstract] Value Health. 2006 Nov; 9(6):A324.
McKenna SP, Meads DM, Doward LC, Tennant A. Improving the scaling properties of the Psychological General Well-Being Scale (PGWB). Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 2005. Washington, DC. [abstract] Value Health. 2005 May; 8(3):380.
Doward LC, Tai SJ, Taylor JL. An exploratory study to develop a model of quality of life for bipolar disorder. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 2005. Washington, DC. [abstract] Value Health. 2005 May; 8(3):390.
Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.
Williams VSL, Fehnel SE, Hollis KA, Hogue SL. Antidepressant-induced sexual dysfunction (ADSD) in Europe: a preliminary investigation. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(4):361-2.
Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.
McKenna SP, Whalley D, Doward LC. Improving the measurement properties of the quality of life in depression scale. Poster presented at the 2002 ISPOR 5th Annual European Congress; November 2002. Rotterdam, The Netherlands. [abstract] Value Health. 2002 Nov 3; 5(6):522.
Irish WD, Neighbors DM, Grogg A, Lopez R, Girts T, Degen K. Performing epidemiological studies in schizophrenia: a propensity score model to predict selection of atypical antipsychotic. Poster presented at the 2002 ISPOR 7th Annual International Meeting; May 2002. Arlington, VA. [abstract] Value Health. 2002 May; 5(1):216.
Neighbors D, Irish WD, Lopez R, Degen K, Swann A, Grogg A. Inpatient medication utilization and costs of risperidone, olanzapine, and quetiapine: a retrospective chart abstraction study. Poster presented at the 2002 ISPOR 7th Annual International Meeting; May 19, 2002. Arlington, VA. [abstract] Value Health. 2002 May; 5(3):234.
Alexeyeva I, Mauskopf JA, Earnshaw SR, Gibson JP, Ascher-Svanum H, Ramsey J. A model comparing olanzapine and ziprasidone in patients with schizophrenia. Poster presented at the 2001 ISPOR 6th Annual International Meeting; May 2001. [abstract] Value Health. 2001 Sep; 4(2):148-9.